Table 2.

Main outcomes of the included studies.

References	Peak ALT		Peak AST		EAD			PNF			Total biliary complications
	MP	CS	MP	CS	MP(%)	CS(%)	p	MP(%)	CS(%)	p	MP(%)	CS(%)	p
Guarrera et al. (10)	560.0 ± 355.5 IU/mL	1358 ± 1208.4 IU/mL*	1154 ± 355.5 IU/mL	3339 ± 3376.9 IU/mL*	5	25	0.08	0	0	ns	10	20	N/A
Dutkowski et al. (22)	1239 (689–2126) U/L	2065 (1331–3596) U/L *	1808 (1133–3547) U/L	2848 (1485–6724) U/L *	20	44*	0.03	0	6	ns	20	46	0.035*
Guarrera et al. (21)	550 IU/mL	900 IU/mL #*	1300 IU/mL	1600 IU/mL #	19	30	0.384	3.2	6.7	0.612	13	43.3	0.001*
Ravikumar et al. (25)	N/A	N/A	417 (84–4681) U/L	902 (218–8786) U/L*	15	22.5	0.734	0	0	ns	N/A	N/A	N/A
Selzner et al. (23)	619 (55–2858) U/L	949 (233–3073) U/L	1182 (167–6700) U/L	1474 (521–5156) U/L	0	0	ns	0	0	ns	N/A	N/A	N/A
Bral et al. (24)	N/A	N/A	1252 (383–2600) U/L	839 (153–2600) U/L	55.6	29.6	0.23	0	0	ns	0	14.8	0.55
van Rijn et al. (26)	966 U/L	1858 U/L*	N/A	N/A	0	10	1.00	0	0	ns	40	55	N/A
Watson et al. (27)	1069 (187–4991) IU/L	787 (155–2238) IU/L	N/A	N/A	NA	NA	N/A	NA	NA	N/A	NA	NA	N/A
Nasralla et al. (18)	N/A	N/A	488.1 (408.9–582.8) U/L	964.9 (794.5–1,172.0) U/L*	10.1	29.9*	0.0002	0.8	0	ns	N/A	N/A	N/A
Ghinolfi et al. (30)	332 (263–610) U/L	428 (303–616) U/L	709.5 (371–1575) U/L	574 (377–1162) U/L	20.0	10.0	1.000	0	0	ns	10.0	0	1.000
Patrono et al. (29)	792 ± 773 U/L	817 ± 540 U/L	1425 ± 1729 U/L	1498 ± 1034 U/L	32	34	1.0	0	0	ns	24	18	0.76
Liu et al. (28)	1357 ± 1492 U/L	2615 ± 2541 U/L*	363 ± 318 U/L	1021 ± 999 U/L*	19	46.4	0.02	0	0	ns	N/A	N/A	N/A

ns, not significant; N/A, non-available;

^*, statistically significant; #, approximate number because only diagram form was available in this included study.